Unpublished data may explain Lemtrada's efficacy...

[MSUK]

Previously unpublished data may explain Lemtrada's efficacy and side effects

Analysis of previously unpublished data from the pivotal phase III trials in the regulatory submissions of alemtuzumab, otherwise known as Lemtrada, indicated that efficiency was associated with long-term depletion of memory T- and B-cells. Whereas rapid hyper-repopulation of immature B-cells in the relative absence of regulatory CD4 and CD8 T-cells create the environment for the generation of secondary B-cell autoimmunity, including anti-drug antibodies...Read more - http://www.ms-uk.org/previously-unpubli ... cts-150617